Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study the investigators are looking at two subtypes of Parkinson Disease (PD); "tremor-dominant" (TD) and postural imbalance and gait disorder (PIGD). This study will use magnet resonance imaging (MRI) to see how the brain reacts while resting and doing a finger-tapping task while on and off PD medication. This study will look at the differences between the two sub-types of PD and healthy volunteers.
The investigators will test the hypothesis that connectivity at rest within the motor cortex and between the motor cortex and motor-associated regions such as the supplementary motor area and the pre motor cortex will not be as strong in PIGD compared to TD (increased activity and functional connectivity in TD group)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tremor Dominant PD | Volunteers with predominantly tremor-related motor symptoms of PD | ||
| Postural Instability & Gait Difficulty PD | Volunteers with primarily walking & balance-related motor symptoms of PD. | ||
| Healthy Controls | Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Correlation coefficients between nodes of the motor network at rest and during a tapping motor task. | A measure of the correlation coefficients between nodes of the motor network at rest and during a tapping motor task between the "OFF" and "ON" dopaminergic medication states in the two motor subtype PD patients. | At time of MRI scan: 12 or more hours after their last dose of dopaminergic medication. |
| Correlation coefficients between nodes of the motor network at rest and during a tapping motor task. | A measure of the correlation coefficients between nodes of the motor network at rest and during a tapping motor task between the "OFF" and "ON" dopaminergic medication states in the two motor subtype PD patients. | At time of 2nd MRI scan: 1 to 3 hours after taking their usual dose(s) dopaminergic medication(s). |
| Second level contrast between Parkinson Disease (PD) and Healthy Controls (HC). | Differences in connectivity as measured by correlation coefficients between nodes of the motor network at rest and during a tapping motor task in PD patients of two motor subtypes and matched healthy controls. | At time of MRI scan: 12 or more hours after their last dose of dopaminergic medication. |
| Measure | Description | Time Frame |
|---|---|---|
| Task-related whole-brain activations. | Secondary outcome measures include task-related whole-brain activations as assessed by changes in blood oxygen-dependent (BOLD) contrast during functional magnetic resonance imaging (fMRI) scanning. | At time of MRI scan, 12 or more hours after their last dose of dopaminergic medication. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with PD according to UK Brain Bank Criteria will be recruited from the UCD Neurology clinic. Controls will be recruited from spouses and from the community
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brian Berman, MD, MS | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado Denver | Aurora | Colorado | 80045 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Task-related whole-brain activations. |
Secondary outcome measures include task-related whole-brain activations as assessed by changes in blood oxygen-dependent (BOLD) contrast during functional magnetic resonance imaging (fMRI) scanning. |
| At time of 2nd MRI scan, 1 to 3 hours after taking their usual dose(s) dopaminergic medication(s). |
| Connectivity between other motor and non-motor brain regions during the tasks. | Secondary outcome measures include measuring the connectivity between other motor and non-motor brain regions during the tasks. | At time of MRI scan,12 or more hours after their last dose of dopaminergic medication. |
| Correlations of brain activity and functional connectivity to structural connectivity measures and behavioral and clinical assessments | Secondary outcome measures include a measure of the correlations of brain activity and functional connectivity to structural connectivity measures as well as behavioral and clinical assessments. | At time of MRI scan. 12 or more hours after their last dose of dopaminergic medication. |
| Correlations of brain activity and functional connectivity to structural connectivity measures and behavioral and clinical assessments | Secondary outcome measures include a measure of the correlations of brain activity and functional connectivity to structural connectivity measures as well as behavioral and clinical assessments. | At time of 2nd MRI scan. 1 to 3 hours after taking their usual dose(s) dopaminergic medication(s). |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |